AbbVie market cap is $188.6 b, and annual revenue was $33.27 b in FY 2019

AbbVie Gross profit (Q3, 2020)7.9 B

AbbVie Gross profit margin (Q3, 2020), %60.9%

AbbVie Net income (Q3, 2020)2.3 B

AbbVie EBIT (Q3, 2020)3.3 B

AbbVie Cash, 30-Sept-20207.9 B

AbbVie EV267.8 B

AbbVie revenue was $33.27 b in FY, 2019 which is a 1.6% year over year increase from the previous period.

AbbVie revenue breakdown by geographic segment: 28.1% from International and 71.9% from United States

USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|

## Revenue | 25.6b | 28.2b | 32.8b | 33.3b |

| 12% | 10% | 16% | 2% |

## Cost of goods sold | 5.8b | 7.0b | 7.7b | 7.4b |

## Gross profit | 19.8b | 21.2b | 25.0b | 25.8b |

| 77% | 75% | 76% | 78% |

## R&D expense | 4.4b | 5.0b | 10.3b | 6.4b |

## General and administrative expense | 5.9b | 6.3b | 7.4b | 6.9b |

## Operating expense total | 10.4b | 11.6b | 18.7b | 13.3b |

## EBIT | 9.4b | 9.6b | 6.4b | 13.0b |

| 37% | 34% | 19% | 39% |

## Interest expense | 965.0m | 1.0b | 1.1b | 1.5b |

## Pre tax profit | 7.9b | 7.7b | 5.2b | 8.4b |

## Income tax expense | 1.9b | 2.4b | (490.0m) | 544.0m |

## Net Income | 6.0b | 5.3b | 5.7b | 7.9b |

## EPS | 3.6 | 3.3 | 3.7 | 5.3 |

USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 6.5b | 6.9b | 7.0b | 7.9b | 8.3b | 8.2b | 7.8b | 8.3b | 8.5b | 8.6b | 10.4b | 12.9b |

## Cost of goods sold | 1.6b | 1.5b | 1.6b | 1.9b | 1.9b | 1.8b | 1.7b | 1.8b | 1.9b | 1.9b | 3.7b | 5.1b |

## Gross profit | 4.9b | 5.4b | 5.4b | 6.0b | 6.3b | 6.4b | 6.1b | 6.4b | 6.6b | 6.7b | 6.7b | 7.9b |

| 75% | 78% | 77% | 76% | 77% | 78% | 78% | 78% | 77% | 77% | 64% | 61% |

## R&D expense | 1.1b | 1.2b | 1.2b | 1.2b | 1.3b | 1.3b | 1.3b | 1.3b | 2.3b | 1.4b | 1.6b | 1.7b |

## General and administrative expense | 1.4b | 1.5b | 1.5b | 1.8b | 1.8b | 1.9b | 1.7b | 1.7b | 1.7b | 1.7b | 3.5b | 2.8b |

## Operating expense total | 2.5b | 2.7b | 2.7b | 3.1b | 3.6b | 3.2b | 3.1b | 3.0b | 3.9b | 3.1b | 6.0b | 4.6b |

## EBIT | 2.4b | 2.7b | 2.7b | 2.9b | 2.8b | 3.2b | 3.0b | 3.4b | 2.6b | 3.6b | 752.0m | 3.3b |

| 37% | 39% | 39% | 37% | 33% | 38% | 38% | 41% | 31% | 42% | 7% | 25% |

## Interest expense | 247.0m | 253.0m | 252.0m | 251.0m | 272.0m | 302.0m | 325.0m | 309.0m | 420.0m | 428.0m | 614.0m | 620.0m |

## Pre tax profit | 2.1b | 2.4b | 2.1b | 2.8b | 2.0b | 2.8b | 2.5b | 807.0m | 2.0b | 3.1b | (693.0m) | 2.5b |

## Income tax expense | 375.0m | 438.0m | 464.0m | 14.0m | 29.0m | 14.0m | 88.0m | 66.0m | 117.0m | 88.0m | 46.0m | 187.0m |

## Net Income | 1.7b | 1.9b | 1.6b | 2.8b | 2.0b | 2.7b | 2.5b | 741.0m | 1.9b | 3.0b | (739.0m) | 2.3b |

## EPS | 1.1 | 1.2 | 1.0 | 1.7 | 1.3 | 1.8 | 1.7 | 0.5 | 1.3 | 2.0 | (0.5) | 1.3 |

USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|

## Cash | 5.1b | 9.3b | 7.3b | 39.9b |

## Accounts Receivable | 4.8b | 5.1b | 5.4b | 5.4b |

## Prepaid Expenses | 3.6b | 4.7b | 1.9b | 2.4b |

## Inventories | 1.4b | 1.6b | 1.6b | 1.8b |

## Current Assets | 16.2b | 21.2b | 16.9b | 49.5b |

## PP&E | 2.6b | 2.8b | 2.9b | 3.0b |

## Goodwill | 15.4b | 15.8b | 15.7b | 15.6b |

## Total Assets | 66.1b | 70.8b | 59.4b | 89.1b |

## Accounts Payable | 9.4b | 10.2b | 1.5b | 11.8b |

## Short-term debt | 402.0m | 6.4b | 5.3b | 3.8b |

## Current Liabilities | 9.8b | 16.6b | 17.2b | 15.6b |

## Long-term debt | 36.4b | 31.0b | 35.0b | 63.0b |

## Total Debt | 36.8b | 37.4b | 40.3b | 66.7b |

## Common Stock | 18.0m | 18.0m | 18.0m | 18.0m |

## Additional Paid-in Capital | 13.7b | 14.3b | 14.8b | 15.2b |

## Retained Earnings | 4.4b | 5.5b | 3.4b | 4.7b |

## Total Equity | 4.6b | 5.1b | (8.4b) | (8.2b) |

## Debt to Equity Ratio | 7.9 x | 7.3 x | -4.8 x | -8.2 x |

## Debt to Assets Ratio | 0.6 x | 0.5 x | 0.7 x | 0.7 x |

## Financial Leverage | 14.3 x | 13.9 x | -7 x | -10.9 x |

USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|

## Net Income | 6.0b | 5.3b | 5.7b | 7.9b |

## Depreciation and Amortization | 1.2b | 1.5b | 1.8b | 2.0b |

## Accounts Receivable | (71.0m) | (391.0m) | (591.0m) | (74.0m) |

## Inventories | (38.0m) | 93.0m | (226.0m) | (231.0m) |

## Accounts Payable | (1.2b) | 425.0m | 190.0m | (1.1b) |

## Cash From Operating Activities | 7.0b | 10.0b | 13.4b | 13.3b |

## Purchases of PP&E | (479.0m) | (529.0m) | (638.0m) | (552.0m) |

## Cash From Investing Activities | (6.1b) | (274.0m) | (1.0b) | 596.0m |

## Short-term Borrowings | (29.0m) | 22.0m | 299.0m | (3.7b) |

## Long-term Borrowings | (6.0b) | (25.0m) | (6.0b) | (1.5b) |

## Dividends Paid | (3.7b) | (4.1b) | (5.6b) | (6.4b) |

## Cash From Financing Activities | (3.9b) | (5.5b) | (14.4b) | 18.7b |

## Net Change in Cash | (3.3b) | 4.2b | (2.0b) | 32.6b |

## Interest Paid | 986.0m | 1.1b | 1.2b | 1.8b |

## Income Taxes Paid | 3.6b | 1.7b | 1.4b |

USD | FY, 2016 |
---|---|

## Revenue/Employee | 915.6k |

## Debt/Equity | 7.9 x |

## Debt/Assets | 0.6 x |

## Financial Leverage | 14.3 x |

AbbVie's Patients was reported to be 52 m in FY, 2019.

FY, 2018 | FY, 2019 | Mar, 2020 | |
---|---|---|---|

## Active Clinical Trials (Oncology) | 200 | ||

## Countries | 175 | 175 | |

## Exploratory Phase Products (Calico) | 8 | ||

## Exploratory Phase Products (Immunology) | 33 | ||

## Exploratory Phase Products (Neuroscience) | 5 | ||

## Exploratory Phase Products (Oncology) | 45 | ||

## Exploratory Phase Products (Other) | 1 | ||

## Manufacturing Facilities | 14 | 14 | |

## Manufacturing and R&D Facilities | 14 | ||

## Partners | 220 | ||

## Patient Support Programs (US) | 90 | ||

## Patients | 30 m | 52 m | |

## Patients Included in Clinical Trials | 104 k | ||

## Patients Included in Clinical Trials (US) | 40 k | ||

## Patients Treated (Immunology) | 1 m | ||

## Phase I Trials Products (Immunology) | 2 | ||

## Phase I Trials Products (Neuroscience) | 3 | ||

## Phase I Trials Products (Oncology) | 18 | ||

## Phase I Trials Products (Other) | 1 | ||

## Phase II Trials Products (Immunology) | 6 | ||

## Phase II Trials Products (Neuroscience) | 2 | ||

## Phase II Trials Products (Oncology) | 3 | ||

## Phase II Trials Products (Other) | 2 | ||

## Phase III Trials Products (Immunology) | 11 | ||

## Phase III Trials Products (Neuroscience) | 1 | ||

## Phase III Trials Products (Oncology) | 13 | ||

## Phase III Trials Products (Other) | 1 | ||

## Preclinical Phase Products (Calico) | 2 | ||

## Preclinical Phase Products (Immunology) | 3 | ||

## Preclinical Phase Products (Oncology) | 7 | ||

## Preclinical Phase Products (Other) | 4 | ||

## Programs | 292 | ||

## Research and Development Centers | 8 | 8 | |

## Suppliers | 51 k |

FY, 2019 | |
---|---|

## Water Withdrawn | 31.70 m cubic meters |

## Water Consumed | 4.33 m cubic meters |

## Waste Generated | 33.40 k metric tons |

## Waste Disposed | 9.80 k metric tons |

## Total Recordable Incident Rate | 0.25 |

## Lost Time Incident Rate | 0.09 |

## Hazardous Waste Generated | 17.70 k metric tons |

## Greenhouse Gas Emissions (Scope 2, Carbon Dioxide) | 250 k metric tons of carbon dioxide equivalent |

## Greenhouse Gas Emissions (Scope 1, Carbon Dioxide) | 315 k metric tons of carbon dioxide equivalent |

## Energy Consumption | 2.11 m MWh |

## Air Emissions (Carbon Dioxide) | 564 k metric tons of carbon dioxide equivalent |

FY, 2019 | FY, 2018 | FY, 2017 | |
---|---|---|---|

Male (Management), percent | 24.6 % | 25.1 % | 25.3 % |

Male (Top Managers), percent | 31 % | 30.9 % | 29.6 % |

Female (Management), percent | 22.7 % | 22.3 % | 22.3 % |

Female (Top Managers), percent | 16.4 % | 16.5 % | 18 % |

Other | 5.2 % | 5.2 % | 4.8 % |

- Source: www.abbvie.com

FY, 2019 | FY, 2018 | FY, 2017 | |
---|---|---|---|

Female, percent | 53.3 % | 53.2 % | 53.4 % |

Male, percent | 46.7 % | 46.8 % | 46.6 % |

- Source: www.abbvie.com